StockData
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) shareholders

APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)

Close on Nov 17, 2026Market cap $5.71MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
20.5%
3M of 13M shares
Institutional holders
28
8 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $61.04K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ryan Wilder
Joint filing with Vestal Point Capital, LP (9.90%)
22,654,8329.90%13G (passive)Mar 31, 2026
Squadron Capital Management LLC
Joint filing with Squadron Master Fund LP (9.90%), William Blank (9.90%) and 1 more
1,271,0819.90%13G (passive)Mar 30, 2026
Soleus GP, LLC
Joint filing with Soleus Private Equity Fund III, L.P. (9.99%), Soleus Private Equity GP III, LLC (9.99%) and 6 more
1,271,0809.99%13G (passive)Apr 1, 2026
Orin Hirschman
Joint filing with AIGH Capital Management LLC (9.90%)
1,186,2949.90%13G (passive) amendmentMar 31, 2026
AIGH Capital Management LLC
Joint filing with Orin Hirschman (9.90%)
651,7479.90%13G (passive) amendmentDec 31, 2025
Jon M. Plexico
Joint filing with Stonepine Capital Management, LLC (5.10%), Stonepine Capital, L.P. (5.10%) and 1 more
286,3955.10%13G (passive) amendmentDec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of APREValueChange% of portfolio
AIGH Capital Management LLC1,015,5418.07%$814.77K–0.05%
Nantahala Capital Management, LLC411,5203.27%$330.16K+205,7600.01%
Vestal Point Capital, LP350,0002.78%$280.81K–0.01%
Sphera Funds Management Ltd.270,0002.14%$216.62K–0.03%
Renaissance Technologies LLC105,8000.84%$84.88K+80,7000.00%
Geode Capital Management, LLC74,8690.59%$60.07K−44,2620.00%
Citadel Advisors LLC58,6000.47%$47.02KNew0.00%
Bnp Paribas Arbitrage, Snc45,2110.36%$36.27K+5,3940.00%
Diadema Partners LP44,9070.36%$36.03KNew0.00%
Vanguard Fiduciary Trust Co38,4640.31%$30.85K–0.00%
Susquehanna International Group, Llp34,9390.28%$28.03K+21,9210.00%
Morgan Stanley25,8300.21%$20.72K+3,5000.00%
Vanguard Capital Management LLC22,8820.18%$18.35K+3,2600.00%
LPL Financial LLC16,0520.13%$12.88K−5,0000.00%
HighTower Advisors, LLC13,8640.11%$11.12K–0.00%
Northern Trust Corp13,7050.11%$11.00KNew0.00%
Persistent Asset Partners Ltd11,4900.09%$9.22KNew0.00%
XTX Topco Ltd10,5650.08%$8.48KNew0.00%
BlackRock, Inc.7,1730.06%$5.76K−1,3310.00%
Tower Research Capital LLC (TRC)3,5900.03%$2.88K−1,5370.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026283M20.5%8 / 65 / 20M0M
Q1 2026222M17.8%7 / 45 / 61M1M
Q4 2025222M13.5%5 / 56 / 61M1M
Q3 2025232M12.9%2 / 56 / 20M0M
Q2 2025232M14.4%1 / 74 / 40M0M
Q1 2025262M15.5%1 / 47 / 10M0M
Q4 2024262M16.5%5 / 55 / 10M0M
Q3 2024222M17.0%1 / 65 / 60M0M
Q2 2024282M18.2%7 / 64 / 31M0M
Q1 2024242M13.3%7 / 63 / 31M0M
Q4 2023201M7.5%1 / 63 / 20M0M
Q3 2023211M7.0%4 / 26 / 10M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

6 funds held APRE in Q2 2026, 17% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of APREValue% of fundAs of
Fidelity Extended Market Index Fund80,9250.64%$72.23K0.00%May 31, 2026
Vanguard Extended Market Index Fund19,6220.16%$15.74K0.00%Jun 30, 2026
Fidelity Total Market Index Fund7,1970.06%$6.42K0.00%May 31, 2026
Fidelity Series Total Market Index Fund5,8510.05%$5.22K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund2,1000.02%$1.87K0.00%May 31, 2026
Diversified Equity Alpha Master Portfolio2890.00%$2320.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Oren GiladPresident/CEO, Director395,6953.14%Mar 16, 2026
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr43,5280.35%Apr 1, 2026
Jean-Pierre BizzariDirector4,1800.03%Jun 17, 2026
Bernd R. SeizingerDirector48,9100.39%Jun 17, 2026
Richard PetersDirector6,2540.05%Jun 17, 2026
Gabriela GruiaDirector4,1800.03%Jun 17, 2026
Rifat PamukcuDirector22,6890.18%Jun 17, 2026
Michael GrissingerDirector6,0240.05%Jun 17, 2026
Marc DueyDirector259,8922.06%Jun 17, 2026
John B. Henneman IiiDirector13,3640.11%Jun 17, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael Grissinger
Director
Jun 16, 2026Award+3,135––6,024
Marc Duey
Director
Jun 16, 2026Award+3,135––259,290
Richard Peters
Director
Jun 16, 2026Award+3,135––6,254
Rifat Pamukcu
Director
Jun 16, 2026Award+3,135––8,581
John B. Henneman Iii
Director
Jun 16, 2026Award+3,135––13,364
Jean-Pierre Bizzari
Director
Jun 16, 2026Award+3,135––4,180
Bernd R. Seizinger
Director
Jun 16, 2026Award+3,135––48,910
Gabriela Gruia
Director
Jun 16, 2026Award+3,135––4,180
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Mar 12, 2026Award+10,095––43,528
Oren Gilad
President/CEO, Director
Mar 12, 2026Award+20,175––393,895
Oren Gilad
President/CEO, Director
Jan 30, 2026Buy+28,100$0.89$25.01K373,720
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Jan 30, 2026Buy+5,700$0.89$5.07K33,433
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Dec 10, 2025Buy+5,000$1.17$5.85K27,733
Marc Duey
Director
Dec 10, 2025Buy+21,459$1.17$25.11K256,155
Marc Duey
Director
Jun 5, 2025Award+1,045––234,696
John B. Henneman Iii
Director
Jun 5, 2025Award+1,045––10,229
Michael Grissinger
Director
Jun 5, 2025Award+1,045––2,889
Rifat Pamukcu
Director
Jun 5, 2025Award+1,045––5,446
Bernd R. Seizinger
Director
Jun 5, 2025Award+1,045––45,775
Gabriela Gruia
Director
Jun 5, 2025Award+1,045––1,045
Jean-Pierre Bizzari
Director
Jun 5, 2025Award+1,045––1,045
Richard Peters
Director
Jun 5, 2025Award+1,045––3,119
Oren Gilad
President/CEO, Director
Apr 3, 2025Buy+3,003$1.87$5.62K343,123
Oren Gilad
President/CEO, Director
Apr 3, 2025Buy+2,497$1.80$4.49K345,620
Oren Gilad
President/CEO, Director
Mar 27, 2025Award+6,725––340,120
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Mar 27, 2025Award+3,365––22,733
Oren Gilad
President/CEO, Director
Oct 23, 2024Buy+500$3.92$1.96K333,395
Marc Duey
Director
Oct 18, 2024Sale−6,462$4.58$29.60K233,651
Marc Duey
Director
Oct 16, 2024Buy+30,000$4.39$131.70K240,113
Oren Gilad
President/CEO, Director
Oct 15, 2024Buy+250$2.90$725332,895
Marc Duey
Director
Oct 14, 2024Buy+190$2.58$490210,113
Oren Gilad
President/CEO, Director
Oct 14, 2024Buy+1,000$2.59$2.59K332,645
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Oct 11, 2024Buy+50$2.46$12319,368
Bernd R. Seizinger
Director
Oct 11, 2024Buy+10,000$2.68$26.80K44,730
Oren Gilad
President/CEO, Director
Oct 10, 2024Buy+150$2.54$381331,645
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Oct 10, 2024Buy+450$2.61$1.17K19,318
Rifat Pamukcu
Director
Jun 20, 2024Award+1,045––4,401
Bernd R. Seizinger
Director
Jun 20, 2024Award+1,045––34,730
Marc Duey
Director
Jun 20, 2024Award+1,045––209,923
John B. Henneman Iii
Director
Jun 20, 2024Award+1,045––9,184
Richard Peters
Director
Jun 20, 2024Award+1,045––2,074
Michael Grissinger
Director
Jun 20, 2024Award+1,045––1,844
Nadeem Q. Mirza
Chief Medical Officer
May 1, 2024Award+6,730––6,730
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Mar 28, 2024Award+3,365––18,868
Oren Gilad
President, CEO, Director
Mar 28, 2024Award+6,725––331,495
John B. Henneman Iii
Director
Mar 13, 2024Buy+6,860$7.29$50.01K8,139
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Mar 13, 2024Buy+1,010$7.29$7.36K15,503
Oren Gilad
President, CEO, Director
Mar 13, 2024Buy+2,000$7.29$14.58K324,770
Bernd R. Seizinger
Director
Mar 13, 2024Buy+6,860$7.29$50.01K33,685
Bernd R. Seizinger
Director
Aug 23, 2023Award+500––26,825
Richard Peters
Director
Aug 23, 2023Award+500––1,029
Rifat Pamukcu
Director
Aug 23, 2023Award+500––3,356
John B. Henneman Iii
Director
Aug 23, 2023Award+500––1,279
Michael Grissinger
Director
Aug 23, 2023Award+500––799
Marc Duey
Director
Aug 23, 2023Award+500––208,878
Bernd R. Seizinger
Director
Jun 7, 2023Buy+6,029$3.68$22.19K26,325
Bernd R. Seizinger
Director
Jun 6, 2023Buy+4,068$3.63$14.77K20,296
Oren Gilad
President, CEO, Director
Mar 9, 2023Award+4,000––322,770
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr
Feb 27, 2023Award+1,000$5.25$5.25K14,493
John P. Hamill
SrVP/CFO/Prin. Fin&Acctg. Off
Jan 30, 2023Award+269,879––269,879

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.46%
1M shares short
Days to cover
2.6
At 0M shares a day
Change since last report
-15.5%
From 1M shares
Short volume, 20 days
41.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aprea Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,375 shares on Aug 27, 2026 over the last 90 days.

See a number that looks wrong?